NCT06730516CompletedEarly phase 1
Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate
Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% Versus Brimionidin Tartrate 0.2% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study
Source: ClinicalTrials.gov · Last updated 12 Dec 2024
Brief summary (registry, in English)
This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- First submitted
- 6 Dec 2024
- Start date
- 24 Jun 2024
- Primary completion date
- 1 Sept 2024
- Lead sponsor
- Zagazig University
- Diseases
- Glaucoma
- NCT number
- NCT06730516
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 56
- From 24 Jun 2024 to the primary completion date, 1 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- optic nerve lesions other than glaucomatous changes patients with previous glaucoma surgery
Who the study is looking for
- age more than 18 years newly diagnosed naive patients with POAG
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zagazig University Coordinator of this site? Confirm its status | Zagazig | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.